Clinical Endpoint Study of Nepafenac 0.3% Opthalmic Suspension
Status:
Completed
Trial end date:
2018-12-18
Target enrollment:
Participant gender:
Summary
A randomized, multicenter, double masked, placebo controlled, parallel group, bioequivalence
study to evaluate the clinical equivalence and safety of Nepafenac 0.3% ophthalmic suspension
(manufactured by Indoco remedies Ltd. for Actavis LLC) with IlevroTM (Nepafenac ophthalmic
suspension), 0.3% of Alcon Laboratories, Inc. for the treatment of pain and inflammation
associated with cataract surgery.